SBRT2015

C O N C L U S I O N S  Clear dose effect relationship in stage I NSCLC and pulmonary metastases  Dose explains well high rates of local tumor control  Dose-response not different between primary NSCLC and pulmonary metastases  PTV encompassing dose >100Gy BED achieves >90% TCP  Total dose adapted to competing risk of death / progression  Fractionation adapted to risk of OAR toxicity

/ Matthias Guckenberger - DEGRO 2015

29.08.2015

36